MyMD Pharmaceuticals, Inc. is presenting data from a preclinical study of investigational, oral TNF- inhibitor MYMD-1 at the 2023 Society of Toxicology Annual Meeting (SOT) in Nashville, TN. Study results comparing MYMD-1 to placebo were very highly significant and showed MYMD-1 reduced histopathological changes and the severity of standard arthritis clinical trial measures. The study was designed to investigate the anti-inflammatory effects of MYMD-1 in a rheumatoid arthritis (RA) model that mimics features of arthritis in humans and included commonly used clinical arthritis endpoints.

Histopathology parameters were very highly significant vs placebo for composite score (p<0.0001), bone resorption (p<0.0001), periosteal/exostatic change (p<0.001), inflammation (p<0.001), pannus/synovial hyperplasia (p<0.001), and in life pawn volume (p<0.001). Disease severity (total composite score) was reduced by 47% with MYMD-1 at 450 mg/kg/day orally versus a 37% reduction for etanercept 10 mg/kg by subcutaneous injection. Poster #3046/P148 entitled "A Naturally Occurring Novel Therapeutic and Oral Selective Inhibitor of TNF-, MYMD-1 (Isomyosamine) Significantly Reduced the Inflammation and Disease Severity in Murine Model of Collagen Antibody-Induced Arthritis," is scheduled for poster presentation March 20, 2023, at 9:00 AM CT.

MYMD-1 is an oral next-generation TNF- inhibitor with the potential to transform the way that TNF- based diseases are treated due to its selectivity and ability to cross the blood brain barrier. MyMD is planningearly-stage trials for rheumatoid arthritis and will provide guidance as the program develops. Study Design: The research model was induced by an intravenous injection of a monoclonal antibodies cocktail that directed to collagen type II on Day 1 (sensitization), followed by an intraperitoneal injection of the endotoxin LPS on Day 6 (boost immunization).

Three doses of MYMD-1 (50, 250 and 450 mg/kg/day) were tested, and the dose formulations were administered by oral gavage, twice daily, starting at the onset of the disease (Day 8 in this study). Etanercept (a biologic TNF- inhibitor) and Dexamethasone (a glucocorticoid) were also administered respectively twice weekly by subcutaneous injection (10 mg/kg) and daily by oral gavage (3 mg/kg) as positive controls.